The American Society of Health System Pharmacists reports that the FDA "directed all makers of ADHD stimulants in May to strengthen the wording in the "Warnings" section of the labeling "with regard to serious cardiovascular events and psychiatric events."
Three essays provide an overview of the bias that has debased the integrity of medical research literature while increasing the hazards of medical practice–for patients and doctors who are kept in the dark about prescribed treatment dangers.
An investigative report in Mercury News (below) focuses on Stanford University department heads, associate deans and other leaders because “these are senior people who set the tone at the medical school and are role models for junior faculty members.”
“There is a crisis of credibility in medicine and science,” says Dr Joseph Sonnabend who, as a former virologist for the Medical Research Council and a retired Aids physician, has watched the basis for public confidence decline.
Health Canada has taken constructive step to warn people with high blood pressure, heart disease and other medical ailments NOT to take psychostimulant drugs–which are essentially amphetamines.
The American Psychiatric Association and child psychiatrists in particular are on a collision course:
A front page article in The New York Times gives a ray of hope about reclaiming medicine from the clutches of industry and its single-minded profit-driven goals:
Three reports illustrate the wide and deepening disconnect between medicine under the influence of pharmaceutical industry marketing goals and scientific evidence that contradicts current practice and public health policies:
Newly published results (phase II) from the CATIE schizophrenia treatment efficacy study sponsored by the National Institute of Mental Health comparing the most commonly used second generation drug treatments for schizophrenia and depression, is highly disturbing.
A report in The New Scientist, "Prescribing of Hyperactivity Drugs is Out of Control," shows just how deviant U.S. prescribing of psychostimulants for
children is compared to the rest of the world.
The Center for Public Integrity reports that FDA officials circumvent the prohibition on accepting trips from drug and medical device manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
